Optimizing Analytical Characterization Upstream & Downstream Purification Strategies to Increase Yield, Protect Quality, & Accelerate Peptide Pipelines
From Novo Nordisk's monumental $6 billion expansion in peptides to Merck's groundbreaking advancements in macrocyclic peptides, and the dynamic collaboration between Genentech and Peptidream, the power of peptides in revolutionizing drug development is undeniable.
But the journey doesn't stop there. As the demand for complex peptides skyrockets and the need for large-scale manufacturing intensifies, the Peptide Process Development & CMC Summit emerged as the beacon guiding you through this exhilarating landscape.
Delegates who joined us in 2024 were in for an immersive experience where innovation met practicality:
- Mastered the art of synthesizing intricate peptide-drug conjugates, cyclic, and macrocyclic peptides, propelling next-generation developments to new heights.
- Unleashed the potential of traditional synthesis and purification techniques, maximizing efficiency and ensuring top-notch quality production.
- Embarked on a voyage of exploration into alternative synthesis processes—biological, solid phase, liquid phase, hybrid—empowering attendees to select the most efficient approach with an eye toward the future.
- Gained invaluable insights into control strategies and CMC requirements, navigating regulatory waters with confidence while maintaining unwavering commitment to quality.
- Scaled up their peptide manufacturing operations, catering to the diverse needs of clinical development and patient populations across a spectrum of diseases.
The ONLY industry-led summit focusing on the synthetic peptide upstream and downstream process development and CMC for seamless technology transfer.
The inaugural Summit united Analytical, Process Development and CMC experts. This exclusive event stands as the sole summit dedicated to synthetic peptide upstream and downstream process development across the next generation of peptides – covering conjugates to cyclic peptides. We were joined by experts from Amgen, Lilly, Merck, and Novartis to revolutionize our approaches and embrace for the future of peptide-driven drug development with confidence and quality in mind.
Our 2024 World-Class Speaker Faculty Included:
Companies Who Attended:
Top Testimonial:
“I feel like so many of the peptide conferences end up veering towards discovery, just because everything is just newer. So, to see this process-focused agenda, is really exciting for industry professionals who are pushing these drugs through the clinical pipeline.”
Timothy White, Senior Director, Eli Lilly
Other Events in the Series:
